82% reduction in the risk for a patient to progress or die under LUTATHERA® (Lutetium (177Lu) oxodotreotide) compared to high-dose (60mg) octreotide long-acting release (LAR).1*


The overall safety profile of LUTATHERA® is based on pooled data from patients from clinical trials (NETTER-1 phase III and Erasmus phase I/II Dutch patients) and from compassionate use programs.1


Improvement in overall global health-related quality of life (HRQoL) up to week 84 for patients on LUTATHERA® as compared to patients on high-dose (60mg) octreotide LAR.1*

*High-dose octreotide LAR 60mg is not the licensed dose.
References: 1. LUTATHERA® Summary of Product Characteristics. January 2021. Available at: https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf Accessed April 2021.